Seres Surges 611% After Colon Therapy Meets Goal in Study

(Bloomberg) -- Small-cap drug developer Seres Therapeutics Inc. soared sevenfold to the highest in four years Monday after a study for its drug in patients with a bacteria-driven colon infection wa...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.